Description
Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer’s Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.
This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.
Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.
A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:
- US
- Europe
- Japan
- Rest of World
as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:
- Eisai Co., Ltd.
- Forest Laboratories
- H. Lundbeck A/S
- Johnson & Johnson
- Merz Pharma GmbH
- Novartis AG
- Pfizer, Inc.
Markets are broken out by drug type:
- Cholinesterase inhibitors
- NMDA antagonists
as well as by product.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.
For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.
Table of Contents
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Scope and Methodology
- Size and Growth of the Market
- Key Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- Overview
- Structural Organization of the Neurological System
- Central Nervous System
- The Brain
- Aging and Alzheimer’s Disease
- Stages of Alzheimer’s Disease
- Risk Factors
- Life Expectancy and the Growing Incidence of Alzheimer’s Disease
- World Demographics
- Prevalence, Incidence and Mortality
- Insurance for the Elderly in the United States
- Generic Competition
- Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
- Dr. Reddy’s and Novartis
- Ranbaxy and Ortho-McNeil Neurologics
CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS
- Overview of Products
- Aricept
- Namenda/Exiba/Axura
- Exelon
- Razadyne
- Other Products
CHAPTER FOUR: RESEARCH AND DEVELOPMENT
- Overview
- Phase III
- AAB-001
- Aricept SR
- Exelon Transdermal Patch (ONO 2540)
- Flurizan
- LY450139
- Memryte
- Namenda Once-Daily
- Rosiglitazone XR
- Xaliproden
- Phase II
- Dimebon
- AC-1202
- Ispronicline
- MEM-3454
- MEM-1003
- AN-1792
- ABT-089
- ACC-001 and QS-21
- AL-108
- CX717
- ELND-005
- Huperzine A
- Immune globulin, intravenous
- LY2062430
- Lecozotan SR
- MK-0249
- MK-0952
- Neramenxane
- NIC5-15
- PRX-03140
- Rasagiline mesylate
- SAM-531
- SGS742
- T 817 MA
- TTP 488
- Phase I
- 933776
- Aricept Transdermal Patch
- AV 965
- AVE 8112
- Bapineuzumab
- CAD-106
- CERE-110
- CTS-21166
- EVP 6124
- GSI 953
- Lecozotan SR
- MEM-1414
- NGX267
- Oxigon
- Paz-417
- PF-4360365
- PF-30804014
- R1450
- R4996/MEM 63908
- SSR 180711
- V 950
- Preclinical Development
- TTP 4000
- AAB-002
- Alzhemed
- BACE Inhibitors (TTP 854)
- CX1739
- E2012
- Gamma-secretase inhibitor
- GSI-136
- MEM-1917
- MPI-442690
- PBT2/PBT3/PBT4
- SAR 110894
CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
- Market Overview
- Market Analysis by Product Type
- Market Analysis by Country
- Competitive Analysis
- Leading Products
CHAPTER SIX: LEADING MANUFACTURERS
- Overview
- Eisai Co., Ltd.
- Forest Laboratories
- H. Lundbeck A/S
- Johnson & Johnson
- Merz Pharma GmbH
- Novartis AG
- Pfizer, Inc.
APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Alzheimer’s Disease Market Analysis: 2005-2012
CHAPTER TWO: INTRODUCTION
- Table 2-1: Alzheimer’s Disease Stages 1-7 and Descriptions
- Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
- Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
- Table 2-3: World Population by Selected Geographical Region, 2007 – 2050
- Figure 2-2: World Population by Selected Geographical Region, 2007-2050
- Table 2-4: Estimated World Population by Age and Geographical Region, 2007
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
- Table 2-5: Percent Population Over 65 by Year and Region
- Figure 2-4: Estimated World Population by Age, 2007 and 2050
- Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer’s Disease* by Region/Country, 2007
- Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer’s Diseases by Region, 2007
- Figure 2-6: World Prevalence of Alzheimer’s Disease Compared to Rest of Population Over Age 65, 2007
- Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)
CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS
- Table 3-1: Comparison of Marketed Alzheimer’s Disease Treatments
- Figure 3-1: Alzheimer Product Sales Analysis, 2005-2007
- Figure 3-2: Aricept Sales Analysis, 2005-2007
- Figure 3-3: Namenda/Exiba/Axura Sales Analysis, 2005-2007
- Figure 3-4: Exelon Sales Analysis, 2005-2007
- Figure 3-5: Razadyne Sales Analysis, 2005-2007
CHAPTER FOUR: RESEARCH AND DEVELOPMENT
- Figure 4-1: Alzheimer’s Disease Treatments in Development, 2005, 2006, and 2007
- Table 4-1: Alzheimer’s Disease Therapies in Development
CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
- Table 5-1: Alzheimer’s Disease Market Analysis, 2005-2007
- Table 5-2: Forecasted Alzheimer’s Disease Market Analysis: 2008-2012
- Figure 5-1: Alzheimer’s Disease Market Analysis: 2005-2012
- Table 5-3: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
- Figure 5-2: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
- Figure 5-3: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
- Table 5-4: Alzheimer’s Disease Market Analysis by Region/Country, 2007
- Figure 5-5: Alzheimer’s Disease Market Analysis by Region/Country, 2007
- Table 5-5: Alzheimer’s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
- Figure 5-6: Alzheimer’s Disease Market Estimated Market Share by Leading Suppliers 2007
- Table 5-6: Alzheimer’s Disease Market Estimated Sales of Top Products 2007
- Figure 5-7 : Alzheimer’s Disease Market Estimated Market Share of Top Products, 2007
CHAPTER SIX: LEADING MANUFACTURERS
- Figure 6-1: Eisai’s Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-2: Forest’s Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-3: Lundbeck’s Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-4: Johnson & Johnson’s Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-5: Merz Pharma’s Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-6: Novartis’ Net Revenues and R&D Expenses for 2006 and 2007
- Figure 6-7: Pfizer’s Net Revenues and R&D Expenses for 2006 and 2007
